Pfizer Inc. set an expectation that it would have the first Phase III efficacy data on its COVID-19 vaccine candidate in October, but that may now be unlikely. The company said on 27 October that the trial's data safety monitoring committee remains blinded to the data and that no analysis has been conducted. The update came with Pfizer's third quarter financial disclosures – when many investors and observers expected the efficacy data might be released.
CEO Albert Bourla said the company would update the public on the results of a conclusive positive or negative data...







